5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
美国保险理赔数据显示,使用5α还原酶抑制剂(5-ARi)联合或不联合α受体阻滞剂(α-B)治疗良性前列腺增生并不能降低膀胱癌的发生风险。
期刊:World Journal of Urology
影响因子:2.9
doi:10.1007/s00345-023-04551-4
Del Giudice, Francesco; Belladelli, Federico; Glover, Frank; Basran, Satvir; Li, Shufeng; Mulloy, Evan; Pradere, Benjamin; Soria, Francesco; Krajewski, Wojciech; Nair, Rajesh; Muncey, Wade; Seranio, Nicolas; Eisenberg, Michael L